D2M Biotherapeutics
Grand Cayman
About D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics. The company is a tumor immunological drug developer that aims to expand the potential of immunotherapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $30.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Apr 2023)
- Phone: (617)586-5012
Industries & Categories
Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/d2m-biotherapeutics-47044 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.